# US 2015/0104442 A1 · Phosphocofilin: cofilin co-localization intensity as a predictor of metastatic recurrence

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104442 A1
- Document ID: US20150104442A1
- Status: Published application
- Kind: A1
- Application number: 14/238,253
- Filed: 2012-08-14
- Published: 2015-04-16
- Earliest claimed: 2011-08-15
- Assignees: King's College London; Albert Einstein College of Medicine of Yeshiva University
- Inventors: John Condeelis; Tony Tsz-Cheong Ng; Gregory Weitsman
- Web page: https://patentgrep.com/patent/US20150104442A1

## CPC

- G01N 33/57515: of the breast
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- G01N 33/57595: {involving intracellular compounds}
- G01N 2440/14: phosphorylation
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Methods and products are provided for determining if a subject having a tumor is at risk of metastasis of the tumor. Specifically, the methods comprise detecting phosphorylated cofilin, and both phosphorylated and non-phosphorylated cofilin; quantifying the phosphorylated cofilin, and the total of phosphorylated and nonphosphorylated cofilin; and determining if a subject having the tumor is likely to experience metastasis of the tumor, based on the ratio of the amount of detected phosphorylated cofilin: total amount of phosphorylated and non-phosphorylated cofilin detected. Further disclosed are the types of tumor metastases that can be determined using the methods provided.

## Claims

### Claim 1

A method of determining if a subject having a tumor is likely to experience metastasis of the tumor comprising contacting a sample of the tumor with (a) a detectable agent that binds phosphorylated cofilin and (b) a detectable agent which binds both phosphorylated cofilin and non-phosphorylated cofilin and quantifying (i) the phosphorylated cofilin bound by (a) and (ii) the total of phosphorylated cofilin and non-phosphorylated cofilin bound by (b), wherein a ratio of the amount of phosphorylated cofilin bound:total amount of phosphorylated cofilin and non-phosphorylated cofilin bound in excess of a predetermined ratio value, or a colocalization intensity value (IF) within the highly colocalized areas marked by (a) and (b) in excess of a predetermined IF value, indicates that the subject having the tumor is likely to experience metastasis of the tumor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the tumor is a breast cancer tumor, or a tumor of the nasopharynx, pharynx, lung, bone, brain, sialaden, stomach, esophagus, testes, ovary, uterus, liver, small intestine, appendix, colon, rectum, gall bladder, pancreas, kidney, urinary bladder, breast, cervix, vagina, vulva, prostate, thyroid or skin.

### Claim 3 (depends on 1)

The method of claim 1, wherein IF is intensity of (a) in pixels of an image of the sample x intensity of (b) in pixels of the image of the sample, optionally first masking out pixels with low Pearson distribution.

### Claim 4 (depends on 1)

The method of claim 1, wherein the tumor is a solid tumor.

### Claim 5 (depends on 1)

The method of claim 1, wherein the sample is a biopsy sample.

### Claim 6 (depends on 1)

The method of claim 1, wherein the sample is surgically removed from the subject.

### Claim 7 (depends on 1)

The method of claim 1, wherein the detectable agent that binds phosphorylated cofilin comprises an antibody, or antigen-binding fragment thereof, that specifically binds phosphorylated cofilin.

### Claim 8 (depends on 1)

The method of claim 1, wherein the detectable agent which binds to phosphorylated cofilin and to non-phosphorylated cofilin comprises an antibody, or antigen-binding fragment thereof, which binds phosphorylated cofilin and which also binds non-phosphorylated cofilin.

### Claim 9 (depends on 1)

The method of claim 1, wherein the detectable agent which binds to phosphorylated cofilin and to non-phosphorylated cofilin and/or the detectable agent which binds to phosphorylated cofilin comprises a fluorescent moiety.

### Claim 10 (depends on 9)

The method of claim 9, wherein both the detectable agents each comprise a fluorescent moiety and wherein the detectable agent that binds to phosphocofilin comprises a different fluorescent moiety from the fluorescent moiety of the detectable agent that binds to phosphorylated cofilin and to non-phosphorylated cofilin.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The method of claim 1, wherein the phosphorylated cofilin and non-phosphorylated cofilin are human cofilin.

### Claim 13 (depends on 1)

The method of claim 1, wherein the cofilin comprises SEQ ID NO:1.

### Claim 14 (depends on 1)

The method of claim 1, wherein the sample is a paraffin-embedded biopsy sample.

### Claim 15 (depends on 1)

The method of claim 1, wherein the detectable agent which binds to phosphorylated cofilin and which binds to non-phosphorylated cofilin comprises an anti-pan-cofilin antibody.

### Claim 16 (depends on 1)

The method of claim 1, wherein the detectable agent which specifically binds to phosphorylated cofilin comprises an anti-phospho-Ser-3-cofilin antibody.

### Claim 17 (depends on 1)

The method of claim 1, wherein the predetermined ratio value is determined from one or more subjects with malignant tumors which have not metastasized.

### Claim 18

(canceled)

### Claim 19 (depends on 1)

The method of claim 1, further comprising administering to the subject found likely to experience metastasis of the tumor an anti-metastatic therapy.

### Claim 20 (depends on 1)

A method of mitigating the risk of metastasis of a tumor in a subject comprising administering to a subject identified by the method of claim 1 as likely to experience metastasis of the tumor an anti-metastatic therapy.

### Claim 21

A kit for determining if a subject having a tumor is likely to experience metastasis of the tumor, the kit comprising (a) a detectable agent that specifically binds phosphorylated cofilin and (b) a detectable agent which binds to phosphorylated cofilin and which binds to non-phosphorylated cofilin, and instructions for use.

### Claim 22

(canceled)

### Claim 23

A computer system comprising a program for determining if a subject having a tumor is likely to experience metastasis of the tumor, the computer system comprising a processor and a memory encoding one or more programs coupled to the processor, wherein the processor effects the one or more programs to quantify phosphorylated cofilin stained with a detectable agent in a sample from the tumor in the subject and quantify total phosphorylated cofilin and un-phosphorylated cofilin stained with a different detectable agent in the sample and determine the ratio thereof.

### Claim at position 24

24-30. (canceled)
